iBiomagazine

Frequency Modulated Möbius Mannequin Precisely Predicts Rhythmic Indicators in Organic and Bodily Sciences.

Motivated by functions in bodily and organic sciences, we developed a Frequency Modulated Möbius (FMM) mannequin to explain rhythmic patterns in oscillatory programs. Not like normal symmetric sinusoidal fashions, FMM is a versatile parametric mannequin that permits deformations to sinusoidal form to accommodate generally seen asymmetries in functions. FMM mannequin parameters are straightforward to estimate and the mannequin is simple to interpret advanced rhythmic knowledge.

We illustrate FMM mannequin in three disparate functions, specifically, circadian clock gene expression, corticoptropin ranges in depressed sufferers and the temporal gentle depth patterns of distant stars. In every case, FMM mannequin is demonstrated to be versatile, scientifically believable and straightforward to interpret. Evaluation of artificial knowledge derived from patterns of actual knowledge, recommend that FMM mannequin suits the information very properly each visually in addition to when it comes to the goodness of match measure complete imply squared error.

An R language based mostly software program for implementing FMM mannequin is offered. Progressive knee joint degeneration happens following removing of a torn meniscus. Nevertheless, there may be important variability within the fee of growth of post-meniscectomy osteoarthritis (OA). Whereas there isn’t any present consensus on the danger elements for growth of knee OA in sufferers with meniscus tears, it’s seemingly that each organic and biomechanical elements play crucial roles.

AAV1-Luc Control Virus
AAV-321	Cell Biolabs	50 ?L	1221.6 EUR
Description: Luciferase control virus of AAV serotype 1.
AAV3-Luc Control Virus
AAV-323	Cell Biolabs	50 ?L	1221.6 EUR
Description: Luciferase control virus of AAV serotype 3.
AAV4-Luc Control Virus
AAV-324	Cell Biolabs	50 ?L	1221.6 EUR
Description: Luciferase control virus of AAV serotype 4.
AAV5-Luc Control Virus
AAV-325	Cell Biolabs	50 ?L	1221.6 EUR
Description: Luciferase control virus of AAV serotype 5.
AAV6-Luc Control Virus
AAV-326	Cell Biolabs	50 ?L	1221.6 EUR
Description: Luciferase control virus of AAV serotype 6.
Lenti-hTERT Antisense virus
G201	ABM	10 ml	882 EUR
Lenti-hTERT-Neo Virus
G204	ABM	10 ml	973.2 EUR
Lenti-Myc T58A Virus
G217	ABM	10 ml	973.2 EUR
Lenti-p53 siRNA Virus
G219	ABM	10 ml	973.2 EUR
Lenti-Ras V12 Virus
G221	ABM	10 ml	973.2 EUR
Lenti-Rb siRNA Virus
G223	ABM	10 ml	973.2 EUR
Mouse alpha 2-Macroglobulin (A2M) ELISA kit
600-720-A2M	Alpha Diagnostics	1 Kit	927.6 EUR
STAT5 Reporter (Luc) - Ba/F3 Cell line
79772	BPS Bioscience	2 vials	2275 EUR
Description: The STAT5 Reporter (Luc)-Ba/F3 cell line is designed for monitoring STAT5 signal transduction pathways. It contains a firefly luciferase gene driven by the STAT5 response element located upstream of the minimal TATA promoter. After activation by cytokines or growth factors, endogenous STAT5 binds to the DNA response elements, inducing transcription of the luciferase reporter gene.
STAT3 Reporter (Luc) - HEK293 Cell line (Puromycin)
79800-P	BPS Bioscience	2 vials	3730 EUR
Description: The STAT3 Reporter (Luc)-HEK293 cell line is designed for monitoring STAT3 signal transduction pathway. It contains a firefly luciferase gene driven by STAT3 response elements located upstream of the minimal TATA promoter. After activation by cytokines and growth factors, endogenous STAT3 binds to the DNA response elements, inducing transcription of the luciferase reporter gene.
IRF Reporter (Luc) - THP-1 Cell line
79858	BPS Bioscience	2 vials	1810 EUR
Description: The Interferon Regulatory Factor (IRF) reporter (Luc)-THP-1 cell line is designed to study the activation and signaling of Cytosolic DNA Sensors (CDS) in human monocytic cell line THP-1. It contains a firefly luciferase gene driven by multimerized ISRE (Interferon Stimulated Response Element) located upstream of the minimal TATA promoter. _x000D_The cGAS-STING pathway acts to detect cytosolic DNA and induce an immune response. Briefly, upon binding DNA, the protein cGAS (cyclic GMP-AMP Synthase) triggers reaction of GTP and ATP to form cGAMP. cGAMP binds to STING (Stimulator of Interferon Genes) which triggers phosphorylation of IRF3 via TBK1. IRF3 can then bind to interferon-stimulated responsive elements (ISRE) in the nucleus and leads to IFN-α/β production. The IRF reporter (Luc)-THP-1 cell line is highly responsive to STING and CDS ligands.
Bald Lentiviral Pseudovirion (Luc-eGFP Dual Reporter)
79988	BPS Bioscience	500 µl x 2	795 EUR
Description: The bald lentiviral pseudovirion was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) as the reporters, driven by a CMV promoter. The bald lentiviral pseudovirion can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors._x000D_
NF-κB Reporter (Luc) - HCT116 Cell Line
60623	BPS Bioscience	2 vials	1095 EUR
Description: NF- B luciferase reporter construct is stably integrated into the genome of HCT-116 cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κ B transcription factors bind to the DNA response elements to induce transcription of the luciferase gene._x000D_The NF- κB-luciferase/HCT-116 cell line is suitable for monitoring the activity of NF-κB signaling in response to stimulants such as the cytokines TNF and IL-1β, pathogen-associated molecular pattern (PAMP) (i.e. flagellin) or endogenous damage-associated molecular pattern (DAMP) molecules (i.e. NOD1 ligand) (see application references). It is also suitable for establishing cell-based screens for inhibitors that target specific NF-κB stimulating molecules. This cell line can be further modified to allow investigation of downstream NF-κB activities as a result of targeted genetic mutation(s).
Foxp3 Reporter (Luc) - Jurkat Recombinant Cell Line
60628	BPS Bioscience	2 vials	7645 EUR
Description: Human Foxp3 luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by a human Foxp3 promoter and an enhancer-like conserved noncoding sequence upstream of the Foxp3 promoter.
NF-κB reporter (Luc) - HEK293 Cell line
60650	BPS Bioscience	2 vials	1365 EUR
Description: The NF-κB reporter (Luc) HEK293 cell line is designed to monitor nuclear factor Kappa B (NF-κB) activity. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or agonists of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. The cell line has been functionally validated in response to human TNF-α, IL-1β, and IL-17.
Lenti-Bmi1 Virus, High Titer
LV608	ABM	5 x 20 ul	1825.2 EUR
Lenti-CDK4 Virus, High Titer
LV609	ABM	5 x 20 ul	1825.2 EUR
Lenti-hTERT Virus, High Titer
LV615	ABM	5 x 20 ul	1825.2 EUR
Lenti-EF1α-hTERT Virus
G706	ABM	10 ml	1094.4 EUR
Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter)
78172-1	BPS Bioscience	100 µl	835 EUR
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I W152C L452R D614G
Spike (B.1.429 Variant) Pseudotyped Lentivirus (Luc Reporter)
78172-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.429 Variant Spike (Genbank Accession #QHD43416.1 with B.1.429 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.429 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.429 variant in a Biosafety Level 2 facility.Spike Mutations in B.1.429 Variant: S13I W152C L452R D614G
Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter)
78204-1	BPS Bioscience	100 µl	835 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility.
Spike (B.1.617 Variant) Pseudotyped Lentivirus (Luc Reporter)
78204-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617 (Kappa, Delta lineage) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617 variant in a Biosafety Level 2 facility.
Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter)
78205-1	BPS Bioscience	100 µl	835 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H
Spike (B.1.617.1 Variant) Pseudotyped Lentivirus (Luc Reporter)
78205-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.1 (also known as the Kappa Variant) was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.617.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.617.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.1 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.617.1 Variant:G142DE154KL452RE484QD614GP681RQ1071H
Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter)
78206-1	BPS Bioscience	100 µl	835 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G
Spike (B.1.618 Variant) Pseudotyped Lentivirus (Luc Reporter)
78206-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants. The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility. Spike Mutations in B.1.618 Variant:Y145delH146delE484KD614G
Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter)
78215-1	BPS Bioscience	100 µl	900 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.
Spike (B.1.617.2 Variant) Pseudotyped Lentivirus (Luc Reporter)
78215-2	BPS Bioscience	500 µl x 2	4510 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2 (also known as the Delta Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter)
78614-1	BPS Bioscience	100 µl	860 EUR
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).
Spike (SARS-CoV-1) Pseudotyped Lentivirus (Luc Reporter)
78614-2	BPS Bioscience	500 µl x 2	4320 EUR
Description: Severe acute respiratory syndrome (SARS) was the first new infectious disease identified in the twenty-first century. It is a viral respiratory disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-1). The first known cases occurred in November 2002, and the syndrome caused the 2002-2004 SARS outbreak. Since 2004, no cases of SARS-CoV-1 have been reported worldwide. A virus very similar to SARS-CoV-1 was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the spread of which started the COVID-19 pandemic.SARS-CoV-1 attaches to the host cell surface before entering the cell. The Spike protein on the virus recognizes and binds to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of human airway epithelia as well as lung parenchyma. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer protection against the viral infection.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses were produced with SARS-CoV-1 Spike (Genbank Accession #YP_009825051.1) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-1) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-1 in a cellular context, using a Biosafety Level 2 facility.The Spike (SARS-CoV-1) Pseudotyped Lentiviruses has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).
NF-κB reporter (Luc) - NIH/3T3 Cell line
79469	BPS Bioscience	2 vials	1900 EUR
Description: The NF-κB reporter (Luc)-NIH/3T3 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene.
NF- κB Reporter (Luc) - THP-1 Cell Line
79645	BPS Bioscience	2 vials	1900 EUR
Description: The NF-κB reporter (Luc)-THP-1 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene.
STAT5 Reporter (Luc)- U937 Cell Line (GM-CSF)
79941	BPS Bioscience	2 vials	1980 EUR
Description: The STAT5 Reporter (Luc)-U937 cell line is designed for monitoring STAT5 signal transduction pathway in the U937 cell line. It contains a firefly luciferase gene driven by the STAT5 response element located upstream of the minimal TATA promoter. After activation by GM-CSF, endogenous STAT5 binds to the DNA response elements, inducing transcription of the luciferase reporter gene.
NF- κB Reporter (Luc) - Raw 264.7 Cell line
79978	BPS Bioscience	2 vials	2045 EUR
Description: The NF-κB reporter (Luc)-Raw 264.7 cell line is designed for monitoring nuclear factor Kappa B (NF-κB) signal transduction pathways. It contains a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene.
PAI-1 Reporter (Luc) - Mv1 Lu Cell Line
60544	BPS Bioscience	2 vials	3595 EUR
Description: PAI-1 Reporter (Luc)-Mv1 Lu cell line is designed for monitoring transforming growth factor β (TGF-β)-induced plasminogen activator inhibitor-1 (PAI-1) expression. Transforming growth factor-β (TGF-β) is a potent regulator of cellular differentiation, proliferation, migration, and protein expression._x000D__x000D_PAI-1 Reporter (Luc) -Mv1 Lu cell line contains a firefly luciferase gene under the control of PAI-1 responsive elements stably integrated into Mv1 Lu (NBL-7) cells, showing TGF-β pathway response. This cell line is validated for the TGF-β response to the induction of PAI-1 gene expression through luciferase activity. _x000D_
NF-κB Reporter (Luc) - CHO-K1 Cell Line
60622	BPS Bioscience	2 vials	1095 EUR
Description: An NF-κB luciferase reporter construct is stably integrated into the genome of CHO-K1 cells. The firefly luciferase gene is controlled by the NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene._x000D_The NF-κB-luciferase / CHO-K1 cell line is suitable for monitoring the activity of NF-κB transcription factor through luminescence readout.). This cell line responds to human cytokine IL-1β, responds moderately to human TNF, and does not respond to human IFN-λ (2 µg/ml). Reducing the amount of serum during incubation period may increase the sensitivity to cytokines. Since CHO-K1 cells do not express endogenous human proteins, this cell line provides an excellent platform to enable exogenous expression of a protein of interest to study its downstream effect on NF-κB signaling.
NF-κB Reporter (Luc) - A549 Stable Cell Line
60625	BPS Bioscience	2 vials	1915 EUR
Description: NF-κB luciferase reporter construct is stably integrated into the genome of A549 cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene.
NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line
60651	BPS Bioscience	2 vials	2340 EUR
Description: NF-κB luciferase reporter construct is stably integrated into the genome of Jurkat T- cells. The firefly luciferase gene is controlled by 4 copies of NF-kB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene.
Rat alpha 2-Macroglobulin (A2M) ELISA kit 96 tests, Quantitative
610-420-A2M	Alpha Diagnostics	1 Kit	927.6 EUR
Human Alpha-2-Macroglobulin (a2M) ELISA Kit
DLR-a2M-Hu-48T	DL Develop	48T	529.2 EUR
Description: A sandwich quantitative ELISA assay kit for detection of Human Alpha-2-Macroglobulin (a2M) in samples from serum, plasma, urine or other biological fluids.
Human Alpha-2-Macroglobulin (a2M) ELISA Kit
DLR-a2M-Hu-96T	DL Develop	96T	684 EUR
Description: A sandwich quantitative ELISA assay kit for detection of Human Alpha-2-Macroglobulin (a2M) in samples from serum, plasma, urine or other biological fluids.
Mouse Alpha-2-Macroglobulin (a2M) ELISA Kit
DLR-a2M-Mu-48T	DL Develop	48T	493.2 EUR
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Alpha-2-Macroglobulin (a2M) in samples from serum, plasma, urine or other biological fluids.
Mouse Alpha-2-Macroglobulin (a2M) ELISA Kit
DLR-a2M-Mu-96T	DL Develop	96T	633.6 EUR
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Alpha-2-Macroglobulin (a2M) in samples from serum, plasma, urine or other biological fluids.
Rat Alpha-2-Macroglobulin (a2M) ELISA Kit
DLR-a2M-Ra-48T	DL Develop	48T	560.4 EUR
Description: A sandwich quantitative ELISA assay kit for detection of Rat Alpha-2-Macroglobulin (a2M) in samples from serum, plasma, urine or other biological fluids.
Rat Alpha-2-Macroglobulin (a2M) ELISA Kit
DLR-a2M-Ra-96T	DL Develop	96T	726 EUR
Description: A sandwich quantitative ELISA assay kit for detection of Rat Alpha-2-Macroglobulin (a2M) in samples from serum, plasma, urine or other biological fluids.
Human Alpha-2-Macroglobulin (a2M) ELISA Kit
RD-a2M-Hu-48Tests	Reddot Biotech	48 Tests	523.2 EUR
Human Alpha-2-Macroglobulin (a2M) ELISA Kit
RD-a2M-Hu-96Tests	Reddot Biotech	96 Tests	721.2 EUR
Mouse Alpha-2-Macroglobulin (a2M) ELISA Kit
RD-a2M-Mu-48Tests	Reddot Biotech	48 Tests	482.4 EUR
Mouse Alpha-2-Macroglobulin (a2M) ELISA Kit
RD-a2M-Mu-96Tests	Reddot Biotech	96 Tests	663.6 EUR
Rat Alpha-2-Macroglobulin (a2M) ELISA Kit
RD-a2M-Ra-48Tests	Reddot Biotech	48 Tests	558 EUR
Rat Alpha-2-Macroglobulin (a2M) ELISA Kit
RD-a2M-Ra-96Tests	Reddot Biotech	96 Tests	771.6 EUR
Human Alpha-2-Macroglobulin (a2M) ELISA Kit
RDR-a2M-Hu-48Tests	Reddot Biotech	48 Tests	546 EUR
Human Alpha-2-Macroglobulin (a2M) ELISA Kit
RDR-a2M-Hu-96Tests	Reddot Biotech	96 Tests	754.8 EUR
Mouse Alpha-2-Macroglobulin (a2M) ELISA Kit
RDR-a2M-Mu-48Tests	Reddot Biotech	48 Tests	502.8 EUR
Mouse Alpha-2-Macroglobulin (a2M) ELISA Kit
RDR-a2M-Mu-96Tests	Reddot Biotech	96 Tests	693.6 EUR
Rat Alpha-2-Macroglobulin (a2M) ELISA Kit
RDR-a2M-Ra-48Tests	Reddot Biotech	48 Tests	583.2 EUR
Rat Alpha-2-Macroglobulin (a2M) ELISA Kit
RDR-a2M-Ra-96Tests	Reddot Biotech	96 Tests	806.4 EUR
Steady-Luc Firefly HTS Assay Kit (10x100 ml)
30028-3	Biotium	1KIT	3774 EUR
Description: Minimum order quantity: 1 unit of 1KIT
Human BM88 Differentiation Reporter (pGreenZeo, Virus)
SR10021VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse Camk2a Differentiation Reporter (pGreenZeo, Virus)
SR10022VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse GAD67 Differentiation Reporter (pGreenZeo, Virus)
SR10023VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Rat NSE Differentiation Reporter (pGreenZeo, Virus)
SR10024VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse MBP Differentiation Reporter (pGreenZeo, Virus)
SR10026VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human Opsin Differentiation Reporter (pGreenZeo, Virus)
SR10027VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human Insulin Differentiation Reporter (pGreenZeo, Virus)
SR10028VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human LCK Differentiation Reporter (pGreenZeo, Virus)
SR10032VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Rat Nestin Differentiation Reporter (pGreenZeo, Virus)
SR10034VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human Nestin Differentiation Reporter (pGreenZeo, Virus)
SR10035VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse ALBP Differentiation Reporter (pGreenZeo, Virus)
SR10036VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human NGN3 Differentiation Reporter (pGreenZeo, Virus)
SR10037VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human PDX1 Differentiation Reporter (pGreenZeo, Virus)
SR10039VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human Osteocalcin Differentiation Reporter (pGreenZeo, Virus)
SR1003VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse PDX1 Differentiation Reporter (pGreenZeo, Virus)
SR10040VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human MAP2 Differentiation Reporter (pGreenZeo, Virus)
SR10047VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human FABP7 Differentiation Reporter (pGreenZeo, Virus)
SR10048VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human ACTC Differentiation Reporter (pGreenZeo, Virus)
SR10049VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human B29 Differentiation Reporter (pGreenZeo, Virus)
SR1004VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse Myogenin Differentiation Reporter (pGreenZeo, Virus)
SR10050VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human GFAP Differentiation Reporter (pRedZeo, Virus)
SR10051VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse B29 Differentiation Reporter (pGreenZeo, Virus)
SR1005VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human NKX2.5 Differentiation Reporter (pGreenZeo, virus)
SR10067VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse CD8 Differentiation Reporter (pGreenZeo, Virus)
SR1006VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse CD68 Differentiation Reporter (pGreenZeo, Virus)
SR1008VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human CD2 Differentiation Reporter (pGreenZeo, Virus)
SR1009VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Oct4 CR4-pGreenFire Response Reporter (virus)
SR20070-VA-1	SBI	>2 x 10^6 IFUs	882 EUR
Mouse Actc Differentiation Reporter (pGreenZeo, Virus)
SR10010VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human Tnnt2 Differentiation Reporter (pGreenZeo, Virus)
SR10012VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse Tnnt2 Differentiation Reporter (pGreenZeo, Virus)
SR10013VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse SM22a Differentiation Reporter (pGreenZeo, Virus)
SR10014VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human GFAP Differentiation Reporter (pGreenZeo, Virus)
SR10015VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse GFAP Differentiation Reporter (pGreenZeo, Virus)
SR10016VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human CD11b Differentiation Reporter (pGreenZeo, Virus)
SR10017VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse EMR1 Differentiation Reporter (pGreenZeo, Virus)
SR10018VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse Col2a1 Differentiation Reporter (pGreenZeo, Virus)
SR1001VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Mouse CD44 Differentiation Reporter (pGreenZeo, Virus)
SR10020VA-1	SBI	>2 x 10^6 IFUs	906 EUR
NF-kB/293/GFP-Luc Transcriptional Reporter Cell Line
TR860A-1	SBI	>2 x 10^6 cells	3915.6 EUR
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter)
78028-1	BPS Bioscience	100 µl	900 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter)
78028-2	BPS Bioscience	500 µl x 2	4510 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_
GLP-1R/CRE (Luc) Reporter - HEK293 Recombinant Cell Line
78176	BPS Bioscience	2 vials	10105 EUR
Description: Recombinant HEK293 cells expressing firefly luciferase gene under the control of cAMP response element (CRE) with constitutive expression of human GLP-1R (Glucagon-like peptide 1 receptor; accession number BC113493)._x000D_GLP-1R, a member of the class B family of G protein-coupled receptors (GPCRs) primarily found in pancreatic β cells, is activated by a peptide hormone, glucagon-like peptide 1 (GLP-1) that is secreted from intestinal L-cells after nutrient ingestion. GLP-1R plays an important role in controlling blood sugar level by enhancing glucose-stimulated insulin secretion, so various research efforts have focused on the regulation of the GLP-1R mediated signaling pathway as a therapeutic approach to diabetes.
Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter)
78348-1	BPS Bioscience	100 µl	900 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951).
Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter)
78348-2	BPS Bioscience	500 µl x 2	4510 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951).
Myc Reporter (Luc) - HCT116 Cell Line (Myc Signaling Pathway)
60520	BPS Bioscience	2 vials	2175 EUR
Description: The Myc Reporter - HCT116 cell line contains the firefly luciferase gene under the control of Myc responsive elements stably integrated into HCT116 cells, a human colon cancer cell line. HCT116 contains a mutated beta-catenin which leads to the accumulation of β -catenin and constitutive activation of downstream Myc that induces the expression of Myc luciferase reporter. The cell line is validated for the inhibition of the expression of Myc luciferase reporter.
GITR / NF-κB-Luciferase Reporter (Luc) - Jurkat Cell Line
60546	BPS Bioscience	2 vials	10175 EUR
Description: This cell line expresses a surface human GITR (glucocorticoid-induced TNFR family related gene; TNFRSF18; CD357) and an NF-κB luciferase reporter construct that are stably integrated into the genome of Jurkat T-cells. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by stimulants, endogenous NF-κB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene. The cells have been validated using purified human GITRL and anti-GITR neutralizing antibody.
CD40/NF-κB Reporter (Luc) - HEK293 Stable Cell Line
60626	BPS Bioscience	2 vials	6825 EUR
Description: Recombinant HEK293 cell line expressing full length human CD40 (Tumor necrosis factor receptor superfamily member 5; TNFRSF5). Expression is confirmed by real-time qPCR and Western Blot. This NF-κB luciferase reporter construct is stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by human CD40 ligand, NF-κB transcription factor binds to the DNA response elements to induce transcription of the luciferase gene. _x000D_
Lenti-Myc T58A Virus, High Titer
LV618	ABM	5 x 20 ul	1825.2 EUR
Lenti-p53 siRNA Virus, High Titer
LV619	ABM	5 x 20 ul	1825.2 EUR
Lenti-Ras V12 Virus, High Titer
LV620	ABM	5 x 20 ul	1825.2 EUR
Lenti-Rb siRNA Virus, High Titer
LV621	ABM	5 x 20 ul	1825.2 EUR
Lenti-hTERT-Neo Virus, High Titer
LV622	ABM	5 x 20 ul	1825.2 EUR
Lenti-HPV-16 E6/E7 Virus
G268	ABM	10 ml	882 EUR
Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter)
78112-1	BPS Bioscience	100 µl	875 EUR
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_
Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter)
78112-2	BPS Bioscience	500 µl x 2	4405 EUR
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_
Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter)
78218-1	BPS Bioscience	100 µl	835 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G.  Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility.
Spike (B.1.617.2.1; Delta Plus Variant) Pseudotyped Lentivirus (Luc Reporter)
78218-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.617.2.1 (also known as the Delta Plus Variant) was identified in India in the spring of 2021. This variant has a number of mutations that increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.617.2.1 Variant Spike (Genbank Accession #QHD43416.1 with B.1.617.2.1 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G.  Compared to the Delta variant (B.1.617.2), variant Delta Plus has an additional mutation, K417N. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.617.2.1 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.617.2.1 variant in a Biosafety Level 2 facility.
GAS Reporter (Luc) - HeLa Cell Line (IFNγ/JAK/STAT1 Pathway)
79041	BPS Bioscience	2 vials	1810 EUR
Description: The GAS reporter (Luc)-HeLa cell line is designed to monitor the activity of interferon gamma-induced signal transduction pathways in cultured cells by measuring activated STAT1 homodimers. It contains a firefly luciferase gene driven by three copies of the interferon gamma-activated sites (GAS) located upstream of the minimal TATA promoter. IFNγ first binds to a heterodimeric receptor consisting of two chains, IFNGR1 and IFNGR2, causing its dimerization and the activation of specific Janus family kinases (JAK1 and JAK2). Two STAT1 molecules associate with this ligand-activated receptor complex and are activated by phosphorylation to form active homodimer. The active STAT1 homodimers translocate to the nucleus where they bind interferon gamma-activated sites (GAS) in the promoter of IFNγ inducible genes, including luciferase reporter gene.
Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter)
79982-1	BPS Bioscience	100 µl	1075 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_ The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_
Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter)
79982-2	BPS Bioscience	500 µl x 2	8110 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_ The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_
GR-GAL4 Reporter (Luc)-HEK293 Cell Line (Glucocorticoid Receptor Pathway)
60655	BPS Bioscience	2 vials	2275 EUR
Description: The Glucocorticoid Receptor Pathway GAL4 Reporter (Luc) - HEK293 Cell Line contains a_x000D_firefly luciferase gene under the control of glucocorticoid receptor ligand binding domain that is_x000D_fused to the DNA binding domain (DBD) of GAL4 (GAL4 DBD-GR) stably integrated into_x000D_HEK293 cells. This fusion construct activates firefly luciferase expression under the control of a_x000D_multimerized GAL4 upstream activation sequence (UAS). This allows for specific detection of_x000D_glucocorticoid-induced activation of the glucocorticoid receptor without the need for individual_x000D_transcriptional targets and with low cross-reactivity for other nuclear receptor pathways. This cell_x000D_line is validated for response to stimulation of dexamethasone and to the treatment with_x000D_mifepristone, an inhibitor of the glucocorticoid signaling pathway.
Mouse Alpha-Tubulin Differentiation Reporter (pGreenZeo, Virus)
SR10025VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human SPP-1 Differentiation Reporter (pGreenZeo, Virus)
SR1002VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human Keratin 14 Differentiation Reporter (pGreenZeo, Virus)
SR10038VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human Doublecortin (DCX) Differentiation Reporter (pGreenZeo, Virus)
SR10041VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human HLA-DRa Differentiation Reporter (pGreenZeo, Virus)
SR1007VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human MLC-2v Differentiation Reporter (pGreenZeo, Virus)
SR10011VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Human GFAP Differentiation Reporter (pGreenZeo, Virus) Puro
SR10015VA-P	SBI	>2 x 10^6 IFUs	906 EUR
Mouse IBA-1 Differentiation Reporter (pGreenZeo, Virus)
SR10019VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Lenti-EF1α-hTERT Virus, High Titer
LV616	ABM	5 x 20 ul	2068.8 EUR
Lenti-CMV-hTERT-GFP-2A-Puro Virus
LV623	ABM	10 ml	1270.8 EUR
Lenti-CMV-hTERT-RFP-2A-Puro Virus
LV625	ABM	10 ml	1270.8 EUR
Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78142-1	BPS Bioscience	100 µl	860 EUR
Description: The Spike (SARS-CoV-2) (B.1.351) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) (B.1.351) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.351 variant in a Biosafety Level 2 facility._x000D_
Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78142-2	BPS Bioscience	500 µl x 2	4320 EUR
Description: The Spike (SARS-CoV-2) (B.1.351) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) (B.1.351) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.351 variant in a Biosafety Level 2 facility._x000D_
Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78143-1	BPS Bioscience	100 µl	835 EUR
Description: The Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with mutations K417T, E484K, and N501Y) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, K417T, E484K, N501Y) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 K417T, E484K, N501Y variant in intact cells using a Biosafety Level 2 facility._x000D_
Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78143-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with mutations K417T, E484K, and N501Y) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, K417T, E484K, N501Y) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 K417T, E484K, N501Y variant in intact cells using a Biosafety Level 2 facility._x000D_
Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78144-1	BPS Bioscience	100 µl	835 EUR
Description: In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank #QHD43416.1 with P.1 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility._x000D_
Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78144-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank #QHD43416.1 with P.1 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility._x000D_
CRE/CREB Reporter (Luc) - Jurkat Cell Line (cAMP/PKA Signaling Pathway)
79636	BPS Bioscience	2 vials	1810 EUR
Description: The CRE/CREB Reporter (Luc) - Jurkat Cell Line contains a firefly luciferase gene under the control of multimerized cAMP response element (CRE) stably integrated into Jurkat cells. Elevation of the intracellular cAMP level activates cAMP response element binding protein (CREB) to bind CRE and induces the expression of luciferase. This cell line is validated for response to stimulation by Forskolin.
CRE/CREB Reporter (Luc) - HEK293 Cell Line (cAMP/PKA Signaling Pathway)
60515	BPS Bioscience	2 vials	2070 EUR
Description: The cAMP/PKA Signaling Pathway CRE/CREB Reporter (Luc) - HEK293 Cell Line is designed for monitoring the activity of the cAMP/ PKA signaling pathway. The cAMP/PKA Signaling Pathway CRE/CREB Reporter (Luc) - HEK293 Cell Line contains a firefly luciferase gene under the control of multimerized cAMP response element (CRE) stably integrated into HEK293 cells. Elevation of the intracellular cAMP level activates cAMP response element binding protein (CREB) to bind CRE and induces the expression of luciferase.
Human E-Cadherin, CDH1 Differentiation Reporter (pGreenZeo, virus)
SR10070VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Sox2 SRR2-pGreenFire Response Reporter, pre-packaged virus
SR20071-VA-1	SBI	>2 x 10^6 IFUs	882 EUR
pLL-CMV-GFP-T2A-Puro [Lenti-LabelerTM virus]
LL100VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-CMV-GFP-T2A-Blast [Lenti-LabelerTM virus]
LL105VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-CMV-RFP-T2A-Puro [Lenti-LabelerTM virus]
LL110VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-CMV-RFP-T2A-Blast [Lenti-LabelerTM virus]
LL115VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-CMV-BFP-T2A-Puro [Lenti-LabelerTM virus]
LL120VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-CMV-BFP-T2A-Blast [Lenti-LabelerTM virus]
LL125VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-CMV-Luciferase-T2A-Puro [Lenti-LabelerTM virus]
LL150VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-EF1a-GFP-T2A-Puro [Lenti-LabelerTM virus]
LL200VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-EF1a-GFP-T2A-Blast [Lenti-LabelerTM virus]
LL205VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-EF1a-RFP-T2A-Puro [Lenti-LabelerTM virus]
LL210VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-EF1a-RFP-T2A-Blast [Lenti-LabelerTM virus]
LL215VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-EF1a-BFP-T2A-Puro [Lenti-LabelerTM virus]
LL220VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-EF1a-BFP-T2A-Blast [Lenti-LabelerTM virus]
LL225VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-EF1a-Luciferase-T2A-Puro [Lenti-LabelerTM virus]
LL250VA-1	SBI	>2x10^6 IFUs	810 EUR
pLL-CMV-rFLuc-T2A-GFP [Lenti-LabelerTM virus]
LL300VA-1	SBI	>2x10^6 IFUs	836.4 EUR
Lenti-HPV-16 E6/E7 Virus, High Titer
LV617	ABM	5 x 20 ul	1704 EUR
A2M 3'UTR Luciferase Stable Cell Line
TU000005	ABM	1.0 ml	1672.8 EUR
A2m 3'UTR Luciferase Stable Cell Line
TU101050	ABM	1.0 ml	Ask for price
A2M 3'UTR GFP Stable Cell Line
TU050005	ABM	1.0 ml	1672.8 EUR
A2m 3'UTR Luciferase Stable Cell Line
TU200007	ABM	1.0 ml	Ask for price
A2m 3'UTR GFP Stable Cell Line
TU250007	ABM	1.0 ml	Ask for price
A2m 3'UTR GFP Stable Cell Line
TU151050	ABM	1.0 ml	Ask for price
Spike (B.1.621, Mu Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78618-1	BPS Bioscience	100 µl	795 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.621 (also known as the Mu Variant) was first identified in Columbia in early 2021. This variant has a number of mutations that may increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.621, Mu Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.621 Variant Spike (Genbank Accession #QHD43416.1 with B.1.621 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G.  These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.621, Mu Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against the B.1.621 variant in a Biosafety Level 2 facility.
Spike (B.1.621, Mu Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78618-2	BPS Bioscience	500 µl x 2	3995 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.621 (also known as the Mu Variant) was first identified in Columbia in early 2021. This variant has a number of mutations that may increase morbidity and mortality and allow the virus to spread more easily and quickly than other variants.The Spike (B.1.621, Mu Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.621 Variant Spike (Genbank Accession #QHD43416.1 with B.1.621 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G.  These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.621, Mu Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against the B.1.621 variant in a Biosafety Level 2 facility.
Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78625-1	BPS Bioscience	100 µl	900 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. The Omicron Variant (B.1.1.529 variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1, BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2, Omicron Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78625-2	BPS Bioscience	500 µl x 2	4510 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. The Omicron Variant (B.1.1.529 variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1, BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2, Omicron Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78645-1	BPS Bioscience	100 µl	835 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants have been divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5.The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2.12.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2.12.1 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2.12.1 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).
Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter)
78645-2	BPS Bioscience	500 µl x 2	4195 EUR
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants have been divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5.The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2.12.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2.12.1 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2.12.1 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).
pMIR-Reporter-RASA1(3
PVTB00444-2a	Lifescience Market	2 ug	427.2 EUR
pMIR-Reporter-IL13(3
PVTB00445-2a	Lifescience Market	2 ug	427.2 EUR
Human Alpha-Actin 2, ACTA2 Differentiation Reporter (pGreenZeo, virus)
SR10068VA-1	SBI	>2 x 10^6 IFUs	906 EUR
Lenti-EF1?¡À-hTERT-Hygro Virus, High Titer
LV632	ABM	5 x 20 ul	2191.2 EUR
Lenti-CMV-hTERT-GFP-2A-Puro Virus, High Titer
LV624	ABM	5 x 20 ul	2191.2 EUR
Lenti-CMV-hTERT-RFP-2A-Puro Virus, High Titer
LV626	ABM	5 x 20 ul	2191.2 EUR
Pooled Virus Library of all Lenti-miR microRNA Precursor Constructs [4 virus aliquots]
PMIRHPLVA-1	SBI	4 virus aliquots	5974.8 EUR
A2M Antibody
43304-100ul	SAB	100ul	302.4 EUR
A2M antibody
70R-15491	Fitzgerald	50 ul	522 EUR
Description: Rabbit polyclonal A2M antibody
A2M Antibody
32318-100ul	SAB	100ul	302.4 EUR
A2M Antibody
49482-100ul	SAB	100ul	399.6 EUR
A2M Antibody
49482-50ul	SAB	50ul	286.8 EUR
A2M antibody
20-S0403GND1-D0	Fitzgerald	10 ml	152.4 EUR
Description: Goat polyclonal Human alpha 2 Macroglobulin antibody
A2M antibody
20-S0411G000-V0	Fitzgerald	10 ml	133.2 EUR
Description: Goat polyclonal Human alpha 2 Macroglobulin antibody
A2M antibody
20-S5040G000-S4	Fitzgerald	10 ml	159.6 EUR
Description: Goat polyclonal Human alpha 2 Macroglobulin antibody
A2M Antibody
ABD6469	Lifescience Market	100 ug	525.6 EUR
A2M Antibody
ABD8174	Lifescience Market	100 ug	525.6 EUR
A2M Antibody
ABD8176	Lifescience Market	100 ug	525.6 EUR

On this perspective paper we assessment the mechanical predictors and the organic predictors of the response of the knee to partial meniscectomy. We assessment the function of patient-based research, in-vivo animal fashions, cadaveric fashions, bioreactor programs, and statistically augmented computational fashions for the examine of meniscus perform and post-meniscectomy OA, offering perception into the essential interaction between biomechanical and biologic elements.